{"abstract":"The National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the invention embodied in the patents and patent applications listed in the Supplementary Information section of this notice to Nulyn Science (\"Nulyn\"), a company located in Paris, France.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/09/02/2026-17991.html","cfr_references":[],"citation":"91 FR 56458","comment_url":null,"comments_close_on":"2026-09-17","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Diabetes and Digestive and Kidney Diseases' Technology Advancement Office on or before September 17, 2026 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2026-17991","effective_on":null,"end_page":56458,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/09/02/2026-17991.xml","html_url":"https://www.federalregister.gov/documents/2026/09/02/2026-17991/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-mifepristone","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-17991?publication_date=2026-09-02","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-09-02/2026-17991/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":209,"last_updated":"2026-09-21 10:15:07 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-02/pdf/2026-17991.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-17991.pdf?1788266717","publication_date":"2026-09-02","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/09/02/2026-17991.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2026-09-02T05:07:11Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":56458,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Mifepristone and Analogues To Treat Hypercortisolism-Related Insulin Resistance Disorders","toc_doc":"Prospective Grant of an Exclusive Patent; Development and Commercialization of Mifepristone and Analogues to Treat Hypercortisolism-related Insulin Resistance Disorders","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.","topics":[],"type":"Notice","volume":91}